NCT05507437View on ClinicalTrials.gov

Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

April 25, 2024

Study Completion Date

April 25, 2024

Conditions
Acute Kidney Injury Due to Sepsis
Interventions
BIOLOGICAL

TIN816 70 mg lyophilisate powder

Recombinant human CD39 enzyme

OTHER

Placebo

0.9% sterile sodium chloride solution

Trial Locations (7)

1340

Novartis Investigative Site, Ottignies

3600

Novartis Investigative Site, Genk

4032

Novartis Investigative Site, Debrecen

24105

Novartis Investigative Site, Kiel

31054

Novartis Investigative Site, Toulouse

46026

Novartis Investigative Site, Valencia

67091

Novartis Investigative Site, Strasbourg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY